News | Oncology Diagnostics | September 18, 2015

EM Imaging Obtains Global License for Early-Stage Colorectal Cancer Detection Agent

Optical imaging agent improves detection of pre-cancerous polyps by 25 percent over colonoscopy

EMI-137, optical imaging agent, detection, early stage, colorectal cancer
system, trial, EMI-137, colorectal cancer, optical imaging agent

System used during the EMI-137 trial

September 18, 2015 — Edinburgh Molecular Imaging Ltd. (EM Imaging) has signed an exclusive global license for a novel optical imaging agent that could improve the detection of early-stage colorectal cancer.

EM Imaging recently signed the licensing agreement with GE Healthcare Ltd. The company will now complete the development of the imaging agent “EMI-137” that can help doctors identify colorectal cancer early.

In a recent scientific study, reported in the scientific journal Nature Medicine, the EMI-137 agent allowed doctors to see more early-stage colorectal cancer (CRC) and precancerous tumors, which can then easily be removed via colonoscopy.  However, screening with a colonoscope, which is currently the most common method, can miss up to 25 percent of precancerous growths, especially smaller, flat lesions.

James Hardwick, M.D., lead investigator on the study said, “Of the 47 precancerous polyps detected in this study, 12 were missed using a standard colonoscope. This underlines how unreliable this method can be, and we therefore welcome life-saving new technology like EMI-137. This agent has the potential to make polyps light up like light bulbs – allowing clinicians to detect and remove more polyps, prevent more cancers and save more lives.”

Evidence that colorectal cancer can be prevented by the removal of pre-cancerous lesions and polyps (abnormal growth of tissue) is strong. The EMI-137 agent can help doctors more easily identify these suspicious lesions, take a sample (biopsy) or remove the lesion completely. Colorectal cancer is the second most common cause of cancer in women and the third most common in men, and is a major cause of death. 

The Phase I/IIa study in 35 subjects (20 healthy volunteers and 15 patients with high risk of CRC) showed that optical molecular imaging using the fluorescent agent is feasible and safe.

Fluorescence colonoscopy in patients receiving intravenous EMI-137 enabled the visualization of all neoplastic polyps that were visible with white light, and additionally, detected previously missed polyps that were not visible with white light alone. This enables the detection of polyps missed by other techniques.

EMI-137 is a water-soluble compound consisting of a 26–amino acid cyclic peptide, conjugated to a fluorescent cyanine dye, that binds to human tyrosine kinase (c-Met), a receptor frequently overexpressed during cancer growth. EMI-137 has the potential on intravenous administration to image a wide range of cancers — including breast, esophageal, ovarian, thyroid, bile duct carcinoma and lung cancer — due to its specific targeting of the c-Met–receptor.

Sian Godwin, head of licensing at GE Healthcare, said, “We’re pleased EM Imaging will develop and commercialize GE-137, as optical agents can be useful in clinical and research settings for a wide range of common diseases. We see broad partnership and licensing across our research and development portfolio as a way to increase access to new technologies in precision medicine, help develop better diagnostics for patients and reduce the cost of healthcare.”

Neville Young, M.D., program manager, Colorectal Therapies Healthcare Technologies Cooperative, said, "The NIHR [National Institute for Health Research]-funded Colorectal Therapies HTC, based at the University of Leeds, drives a national network of clinicians and academics who are funded to support the development of innovative new technologies that have the potential to benefit patients affected by colorectal disease. We are excited to be working with EM Imaging to help demonstrate both the cost effectiveness and clinical efficacy of their new colorectal tumo r tagging peptide. This technology offers the possibility to identify and remove more easily any cancerous polyps in a patient undergoing a colonoscopy.”

For more information: www.edinimage.com

Related Content

Most research on sleep is conducted using electroencephalography (EEG), a method that entails measuring brain activity through electrodes placed along a patient's scalp. However, Anjali Tarun, a doctoral assistant at EPFL's Medical Image Processing Laboratory within the School of Engineering, decided to investigate brain activity during sleep using magnetic resonance imaging, or MRI.

Getty Images

News | Magnetic Resonance Imaging (MRI) | January 26, 2021
January 26, 2021 — Our state of consciousness changes significantly during stages of deep sleep, just as it does in a
Steinberg Diagnostic Medical Imaging headquarters.

Steinberg Diagnostic Medical Imaging headquarters.

Sponsored Content | Case Study | Contrast Media Injectors | January 21, 2021
Steinberg Diagnostic Medical Imaging (SDMI) was founded 30 years a
According to a new research report1 on the contrast media injectors published by MarketsandMarkets, the market was estimated to be $1.3 billion in 2020 and projected to reach $1.9 billion by 2025, at a compound annual growth rate (CAGR) of 7.4 percent over 2020-2025.

The ulrich CTmotion

Feature | Contrast Media Injectors | January 20, 2021 | By Melinda Taschetta-Millane
According to a new...
Myocarditis among recovering COVID-19 athletes less common than previously reported

Getty Images

News | Cardiac Imaging | January 11, 2021
January 11, 2021 — In a letter published in the December issue of the American Heart Association's...
Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound.

Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound. Image courtesy of UVA Health

News | Focused Ultrasound Therapy | January 08, 2021
January 8, 2021 — A scalpel-free alternative to brain surgery has the potential to benefit people with...
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...